Phase 1/2 study of WTX-330
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs WTX-330 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 17 Jan 2025 New trial record
- 13 Jan 2025 According to a Werewolf Therapeutics media release, company plans to initiate this study of dose- and regimen-finding clinical trial in the first quarter of 2025 to optimize the delivery of WTX-330 to the tumor microenvironment; and Pending data, open expansion arms in selected tumor types.